FedEx Corporation vs Mesoblast Limited — how do they compare? FedEx Corporation trades at $322.43 (market cap $76.28B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: FedEx Corporation is far larger — about 34.5× Mesoblast Limited's market cap, and FedEx Corporation pays a 1.51% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| FDX | MESO | |
|---|---|---|
Market Cap | $76.28B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $338.75 | $20.96 |
52-Week Low | $180.51 | $12.88 |
Enterprise Value | $105.91B | $2.21B |
Dividend Yield | 1.51% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →